Abstracts tagged "Pediatric rheumatology and systemic lupus erythematosus (SLE)"

Abstract Number: 400 • 2015 ACR/ARHP Annual Meeting
Disease Activity and Health Care Utilization Among Young Adults with Childhood-Onset Lupus Transitioning to Adult Care: Data from the Pediatric Lupus Outcomes Study
Erica F. Lawson¹ and Aimee O. Hersh², ¹Pediatrics/Rheumatology, UC San Francisco, San Francisco, CA, ²Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Individuals with childhood-onset systemic lupus erythematosus (cSLE) must transfer from pediatric- to adult-oriented health care as they enter adulthood. However, few studies have assessed…
Abstract Number: 2043 • 2015 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products Have High Sensitivity and Specificity in Childhood-Onset Systemic Lupus Erythematosus and Juvenile Idiopathic Arthritis
Anca Askanase¹, Joyce Hui-Yuen², John Conklin³, Derren Barken⁴, Tyler O'Malley⁵, Xiao Qing Li⁶, Liza Mariel Bermudez², Andrew Eichenfield⁷, Amy J. Starr⁸, Lisa F. Imundo^9,10 and Thierry Dervieux¹¹, ¹Columbia University College of Physicians & Surgeons, New York, NY, ²Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵Research and Development, Exagen Diagnostics, Vista, CA, ⁶Adult Rheumatology, Columbia University Medical Center, New York, NY, ⁷Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, ⁸Columbia University Medical Center, New York, NY, ⁹Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, ¹⁰New York Presbyterian Hospitsl, Columbia University, New York, NY, ¹¹Research and Development, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CBCAPS) have been demonstrated to be sensitive and…
Abstract Number: 1299 • 2014 ACR/ARHP Annual Meeting
A Cross-Sectional Study of Mental Health Symptoms and Mental Health Care in Pediatric SLE/MCTD Patients and Their Peers
Andrea Knight^1,2, Michelle Vickery¹, Pamela Weiss^1,2,3, Knashawn Morales³ and Ron Keren^3,4, ¹Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ²Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Mental health problems are prevalent in pediatric systemic lupus erythematosus (SLE). We aimed to compare the rates of mental health problems and mental health…
Abstract Number: 1296 • 2014 ACR/ARHP Annual Meeting
Pulse- Pediatric Update on Lupus in South Africa: Epidemiology and Management
Laura Lewandowski¹, Laura Schanberg¹, Nathan Thielman² and Christiaan Scott³, ¹Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ²Duke Hubert Yeargan Center for Global Health, Durham, NC, ³Rheumatology, Red Cross War Memorial Children's Hospital, Cape Town, South Africa
Background/Purpose: In developed nations, SLE is more common and severe in people of African extraction than in Caucasians; however, the epidemiology of SLE in Africa…
Abstract Number: 1295 • 2014 ACR/ARHP Annual Meeting
Childhood-Onset Systemic Lupus Erythematosus: Short-Term Treatment Response Rates in Proliferative Lupus Nephritis
Andrea Human¹, Simon Yu Tian², Earl D. Silverman³ and Deborah M. Levy¹, ¹Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ²Rheumatology and Program of Child Health Evaluative Sciences, The Hospital for Sick Children, Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Proliferative Lupus Nephritis (PLN) occurs in up to 50% of patients with childhood-onset systemic lupus erythematosus (cSLE). PLN is a significant source of morbidity and…
Abstract Number: 672 • 2014 ACR/ARHP Annual Meeting
Favorable Response to Belimumab in Pediatric-Onset Systemic Lupus Erythematosus
Joyce Hui-Yuen¹, Jennifer Taylor², Xiao Qing Li³, Liza Mariel Bermudez¹, Josephine Isgro¹, Andrew H. Eichenfield⁴, Amy J. Starr⁴, Lisa F. Imundo⁵, Jill P. Buyon⁶, Richard Furie⁷, Diane L. Kamen⁸, Susan Manzi⁹, Michelle Petri¹⁰, Rosalind Ramsey-Goldman¹¹, Ronald van Vollenhoven¹², Daniel J. Wallace¹³ and Anca Askanase⁴, ¹Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ²Pediatrics, Columbia University Medical Center, New York, NY, ³Adult Rheumatology, Columbia University Medical Center, New York, NY, ⁴Columbia University Medical Center, New York, NY, ⁵Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, ⁶Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁷Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ⁸Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹⁰Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, IL, ¹²Karolinska Institute, Stockholm, Sweden, ¹³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-lymphocyte stimulator. It was approved by the FDA in 2011 for treatment of active,…
Abstract Number: 10 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and Neuropsychiatric Events in Pediatric Patients
Mileka Gilbert¹ and Lenore M. Buckley², ¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ²Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: An association between anti-phospholipid antibodies (aPL abs) and non-thrombotic neuropsychiatric events has been reported in pediatric and adult patients, including patients who do not…
Abstract Number: 2679 • 2013 ACR/ARHP Annual Meeting
Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication Use
Linda T. Hiraki¹, Candace H. Feldman², Mary Beth Son³, Jessica M. Franklin⁴, Michael A. Fischer⁴, Daniel H. Solomon⁵, Seoyoung C. Kim⁶, Wolfgang C. Winkelmayer⁷ and Karen H. Costenbader², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Division of Nephrology, Stanford University School of Medicine, Stanford, CA
Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication UseBackground/Purpose: We investigated incidence rates…
Abstract Number: 1785 • 2013 ACR/ARHP Annual Meeting
Structural Determinants Of Low Vertebral Strength In Pediatric Systemic Lupus Erythematosus
Jon M. Burnham¹, Babette S. Zemel¹, David C. Lee², Tony M. Keaveny³ and Mary Beth Leonard¹, ¹Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²O.N. Diagnostics, LLC, Berkeley, CA, ³Founder and Chief Science Officer, University of California, Berkeley, CA and O.N. Diagnostics, LLC, Berkeley, CA
Background/Purpose: Children with systemic lupus erythematosus (SLE) are at high risk for bone fragility. Studies in pediatric SLE using two-dimensional lumbar spine (LS) dual X-ray…
Abstract Number: 1716 • 2013 ACR/ARHP Annual Meeting
Childhood-Onset Systemic Lupus Erythematosus With Clinical Neurocognitive Dysfunction Have Lower Nodal Density and Connectivity On Diffusion Tensor Imaging
Jordan T. Jones¹, Mark DiFrancesco², Ahmad I. Zaal¹, Marisa S. Klein-Gitelman³, Darren Gitelman⁴, Jun Ying⁵ and Hermine Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Children's Memorial Hospital, Chicago, IL, ⁴Neurology, Northwestern University, Chicago, IL, ⁵Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH
Background/Purpose: Neurocognitive dysfunction (NCD) is common in childhood-onset systemic lupus erythematosus (cSLE), and often difficult to detect with current resources. Diffusion tensor imaging (DTI) is…
Abstract Number: 1615 • 2013 ACR/ARHP Annual Meeting
Type I Interferons As a Serum Biomarker Of Subclinical Atherosclerosis In Pediatric Systemic Lupus Erythematosus Patients
Smriti Mohan¹, Julie Barsalou², Timothy J. Bradley³, Cameron Slorach³, Lawrence Ng⁴, Deborah M. Levy⁵, Earl D. Silverman² and Mariana J. Kaplan⁶, ¹Pediatric Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁶Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder with a marked increase in cardiovascular (CV) morbidity and mortality due to premature atherosclerosis, distinct…
Abstract Number: 1257 • 2013 ACR/ARHP Annual Meeting
Feasibility and Clinical Implications Of The Pediatric Automated Neuropsychological Assessment Metrics for Screening Of Childhood-Onset Neuropsychiatric Systemic Lupus Erythematosus
Patricia Vega-Fernandez¹, Natasha M. Ruth², Deborah M. Levy³, Frank Zelko⁴, Eyal Muscal⁵, Marisa S. Klein-Gitelman⁶, HaiMei Liu⁷, Adam Huber⁸, Jiha Lee⁹, Jessica Hummel⁹, Lori B. Tucker¹⁰, Tresa Roebuck-Spencer¹¹ and Hermine Brunner^12,13, ¹Division of Rheumatology, Cincinanti Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ³Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Pediatric Neuropsychology Service, Children's Memorial Hospital, Chicago, IL, ⁵TCH Pediatric Rheum Center, Baylor College of Medicine, Houston, TX, ⁶Division of Rheumatology, Children's Memorial Hospital, Chicago, IL, ⁷Children's Hospital of Fundan University, Shanghai, China, ⁸IWK Health Centre, Halifax, NS, Canada, ⁹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ¹¹Cognitive Science Research Center, University of Oklahoma, Norman, OK, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Neuropsychiatric disease is common in childhood-onset Systemic Lupus Erythematosus (cSLE). Signs of cNPSLE can be subtle and difficult to ascertain in daily clinical practice.…
Abstract Number: 1263 • 2013 ACR/ARHP Annual Meeting
Childhood-Onset Systemic Lupus Erythematosus In Ontario: Long Term Outcomes In a Population-Based Cohort With Universal Health Care Coverage
Deborah M. Levy¹, Nadia Gunraj², Janet E. Pope³, J. Carter Thorne⁴, Wesley Fidler⁵, Peter B. Dent⁶, Johannes Roth⁷, Roberta A. Berard⁸, Murray Berall⁹, Astrid Guttmann¹⁰ and Earl D. Silverman¹¹, ¹Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Medicine/Rheumatology, St. Joseph's Health Care, University of Western Ontario, London, ON, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵Rheumatology, St. Joseph's Hospital, Thunder Bay, ON, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸Children's Hospital of Western Ontario, London, ON, Canada, ⁹Nephrology, Humber River Regional Hospital, Toronto, ON, Canada, ¹⁰Pediatrics, Institute for Clinical Evaluative Sciences, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹¹Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Little is known about the long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care; however, linking clinical data to administrative…
Abstract Number: 1264 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Quality Indicators and Disease Damage In Childhood-Onset Systemic Lupus Erythematosus Patients
Julia G. Harris^1,2, Kristyn I. Maletta³, Evelyn M. Kuhn³ and Judyann C. Olson^1,2, ¹Medical College of Wisconsin, Milwaukee, WI, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³National Outcomes Center, Children's Hospital of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect virtually every organ system and may lead to significant morbidities. A…
Abstract Number: 1267 • 2013 ACR/ARHP Annual Meeting
Impact Of Disease Duration On Vascular Surrogates Of Early Atherosclerosis In Childhood-Onset Systemic Lupus Erythematosus
Julie Barsalou¹, Timothy J. Bradley², Cameron Slorach², Lawrence W.K. Ng³, Deborah M. Levy⁴ and Earl D. Silverman¹, ¹Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Cardiovascular disease is a leading cause of morbidity and mortality in adults with systemic lupus erythematosus. Exposure to atherogenic risk factors in childhood-onset SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].